There's certainly no shortage of efforts
out there to make glucose monitoring a bit easier
for diabetics, but Freedom Meditech is now claiming to have developed one of the least invasive to date and, what's more, it says it's actually gearing up to start some clinical trials. That latter bit is apparently possible thanks to a newly formed partnership with Batelle, which is helping to raise the necessary capital, while the former bit got a boost from an arrangement with the University of Toledo, whose technology it is licensing. The key bit, it seems, is that Freedom Meditech's method involves scanning only the front portion of the eye (or, more specifically, the Aqueous humor where the glucose resides) instead of shining a light on the retina, which some similar methods use. That apparently not only delivers results faster, but reduces the risk of any potential long-term safety hazards from repeated laser exposure, which would also make it better suited as a tool for early screening of diabetes.